Raloxifene Use for The Heart

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Raloxifene Hydrochloride

Criteria

Inclusion Criteria:

• Postmenopausal women with established coronary heart disease or at risk for a major coronary event.

Exclusion Criteria:

• Postmenopausal symptoms that required estrogen replacement therapy.

• Suspected or known history of breast or endometrial carcinoma.

• Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis.

• New York Heart Association classes III or IV heart failure.